{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:52:14Z","timestamp":1790218334913,"version":"4.1.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbamcr.2026.120136","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:44:58Z","timestamp":1773474298000},"page":"120136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of IL-6 in rheumatoid arthritis comorbidity and implications for therapy"],"prefix":"10.1016","volume":"1873","author":[{"given":"Federica","family":"Monaco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Dimonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbamcr.2026.120136_bb0005","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/OARRR.S523778","article-title":"Impact of biological therapies on quality of life in rheumatoid arthritis: a narrative review","volume":"17","author":"Mamasaidov","year":"2025","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0010","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"The use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/1759720X10378372","article-title":"The role of interleukin 6 in the pathophysiology of rheumatoid arthritis","volume":"2","author":"Srirangan","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrrheum.2013.8","article-title":"The problem of choice: current biologic agents and future prospects in RA","volume":"9","author":"Choy","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0025","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0030","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/1744666X.4.2.165","article-title":"Tocilizumab for the treatment of rheumatoid arthritis","volume":"4","author":"Mima","year":"2008","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0040","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1016\/j.febslet.2011.03.023","article-title":"Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases","volume":"585","author":"Tanaka","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0045","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0050","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","article-title":"Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation","volume":"14","author":"Hurst","year":"2001","journal-title":"Immunity"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0055","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.191.6.915","article-title":"Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling","volume":"191","author":"Teague","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","article-title":"Interleukin-6 signaling drives fibrosis in unresolved inflammation","volume":"40","author":"Fielding","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4049\/jimmunol.2300114","article-title":"Th1 cells alter the inflammatory signature of IL-6 by channeling STAT transcription factors to Alu-like retroelements","volume":"211","author":"Millrine","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0075","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of interleukin-6 by dendritic cells is required for priming pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0080","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.amjmed.2008.06.011","article-title":"Cardiovascular morbidity and mortality in rheumatoid arthritis","volume":"121","author":"Gabriel","year":"2008","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0085","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0090","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10787-018-0458-0","article-title":"IL-6 signalling pathways and the development of type 2 diabetes","volume":"26","author":"Akbari","year":"2018","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0095","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41574-025-01114-y","article-title":"Insulin resistance in type 2 diabetes mellitus","volume":"21","author":"Accili","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0100","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2022-eular.3884","article-title":"Ab0309 association between rheumatic disease comorbidity index and pulmonary involvement in rheumatoid arthritis","volume":"81","author":"Hannech","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0105","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.4049\/jimmunol.1302470","article-title":"Blockade of IL-6 trans signaling attenuates pulmonary fibrosis","volume":"193","author":"Le","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/clim.1999.4736","article-title":"Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis","volume":"92","author":"Voulgari","year":"1999","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0115","first-page":"2177","article-title":"Association of anemia and physical disability among patients with rheumatoid arthritis","volume":"34","author":"Han","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0125","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/324073a0","article-title":"Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin","volume":"324","author":"Hirano","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0130","doi-asserted-by":"crossref","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","article-title":"Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells","volume":"84","author":"Gauldie","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0135","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/bj2240505","article-title":"The acute-phase response of cultured rat hepatocytes. System characterization and the effect of human cytokines","volume":"224","author":"Koj","year":"1984","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0140","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0022-1759(85)90309-6","article-title":"A simple bioassay for monocyte-derived hepatocyte stimulating factor: increased synthesis of alpha 2-macroglobulin and reduced synthesis of albumin by cultured rat hepatocytes","volume":"76","author":"Koj","year":"1985","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-94-024-0921-5_4","article-title":"Regulation of IL-6 in immunity and diseases","volume":"941","author":"Tanaka","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1749-6632.1989.tb24028.x","article-title":"Regulation of expression of interleukin-6. Molecular and clinical studies","volume":"557","author":"Ray","year":"1989","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0160","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1523\/JNEUROSCI.19-13-05236.1999","article-title":"Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor","volume":"19","author":"Van Wagoner","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0165","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0175","first-page":"210","article-title":"gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities","volume":"35","author":"Nakashima","year":"1998","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0180","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0092-8674(94)90235-6","article-title":"Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway","volume":"77","author":"Akira","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0185","series-title":"Differential Functional Coupling in Gp130-JAK Complexes Expands the Plasticity of the Interleukin-6 Signaling Axis","author":"McFarlane","year":"2023"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0092-8674(89)90438-8","article-title":"Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130","volume":"58","author":"Taga","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0195","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3000281","article-title":"Soluble receptors for cytokines and growth factors: generation and biological function","volume":"300","author":"Rose-John","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0200","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.170.4.1409","article-title":"Soluble cytokine receptors are present in normal human urine","volume":"170","author":"Novick","year":"1989","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10384-007-0461-2","article-title":"Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients","volume":"51","author":"Shoji","year":"2007","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0210","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1203\/00006450-199612000-00011","article-title":"Soluble receptors and cytokine antagonists in human milk","volume":"40","author":"Buescher","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00296-010-1593-0","article-title":"Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity","volume":"31","author":"Rodr\u00edguez-Rodr\u00edguez","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0220","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1084\/jem.189.3.599","article-title":"C-reactive protein: a physiological activator of interleukin 6 receptor shedding","volume":"189","author":"Jones","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0225","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3389\/fimmu.2016.00479","article-title":"Expanding diversity in molecular structures and functions of the IL-6\/IL-12 heterodimeric cytokine family","volume":"7","author":"Hasegawa","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0235","first-page":"80","article-title":"Regulation of leukocyte recruitment during acute inflammation by IL-6 and its soluble receptor","author":"Hurst","year":"2001","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0240","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.4049\/jimmunol.171.6.3202","article-title":"Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130","volume":"171","author":"Nowell","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0245","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0250","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4049\/jimmunol.182.1.613","article-title":"Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis","volume":"182","author":"Nowell","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0255","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0260","doi-asserted-by":"crossref","first-page":"26059","DOI":"10.1074\/jbc.M115.649509","article-title":"Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles","volume":"290","author":"Schumacher","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.119135","article-title":"The role of proteolysis in interleukin-11 signaling","volume":"1869","author":"Lokau","year":"2022","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0270","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s12276-020-00531-5","article-title":"Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway","volume":"52","author":"Ng","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0275","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.celrep.2016.01.053","article-title":"Proteolytic cleavage governs interleukin-11 trans-signaling","volume":"14","author":"Lokau","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103309","article-title":"A single aromatic residue in sgp130Fc\/olamkicept allows the discrimination between interleukin-6 and interleukin-11 trans-signaling","volume":"24","author":"Lokau","year":"2021","journal-title":"iScience"},{"issue":"Suppl. 1","key":"10.1016\/j.bbamcr.2026.120136_bb0285","first-page":"S11","article-title":"Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis","volume":"65","author":"Cronstein","year":"2007","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0290","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1084\/jem.187.4.461","article-title":"Interleukin 6 is required for the development of collagen-induced arthritis","volume":"187","author":"Alonzi","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0295","doi-asserted-by":"crossref","first-page":"8222","DOI":"10.1073\/pnas.95.14.8222","article-title":"Interleukin 6 plays a key role in the development of antigen-induced arthritis","volume":"95","author":"Ohshima","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0305","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/765624","article-title":"The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis","volume":"2011","author":"Hashizume","year":"2011","journal-title":"Arthritis"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0310","article-title":"Association between interleukin-6(IL-6) and thrombocytosis in rheumatoid arthritis patients","year":"2016","journal-title":"ResearchGate"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0315","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0320","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1136\/ard.2008.094151","article-title":"Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation","volume":"68","author":"van Halm","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.bbamcr.2026.120136_bb0325","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0268-9499(05)80014-1","article-title":"Assessment of coagulation and fibrinolysis in synovial fluid of rheumatoid arthritis patients","volume":"8","author":"Puccetti","year":"1994","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0330","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00296-003-0289-0","article-title":"Pathologic thrombopoiesis of rheumatoid arthritis","volume":"23","author":"Ertenli","year":"2003","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2025.100842","article-title":"Circulating membrane aminophospholipids contribute to thrombotic risk in rheumatoid arthritis","volume":"66","author":"Costa","year":"2025","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0340","first-page":"451","article-title":"Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade","volume":"34","author":"Gualtierotti","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0345","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#","article-title":"High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors","volume":"44","author":"del Rinc\u00f3n","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0350","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/ard.2006.059980","article-title":"Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?","volume":"67","author":"Gonzalez","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0355","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/heartjnl-2018-314230","article-title":"Inflammation and atherosclerosis: what is on the horizon?","volume":"106","author":"Ruparelia","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0360","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.atherosclerosis.2008.07.031","article-title":"Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)","volume":"203","author":"Saremi","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0365","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0370","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.RES.0000115557.25127.8D","article-title":"Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor","volume":"94","author":"Wassmann","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0375","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH09-05-0297","article-title":"How much is too much? Interleukin-6 and its signalling in atherosclerosis","volume":"102","author":"Schuett","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0380","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":"Interleukin-6 as a key player in systemic inflammation and joint destruction","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0385","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1093\/rheumatology\/keaa725","article-title":"The role of interleukin-6 trans-signalling on cardiovascular dysfunction in inflammatory arthritis","volume":"60","author":"Davies","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0390","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.41095","article-title":"Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial","volume":"72","author":"Giles","year":"2020","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0395","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/rheumatology\/keu224","article-title":"Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment","volume":"53","author":"Choy","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0400","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/ard.2008.101964","article-title":"Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions","volume":"68","author":"Choy","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0410","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10238-022-00816-1","article-title":"Mechanistic and therapeutic links between rheumatoid arthritis and diabetes mellitus","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0415","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10753-021-01559-z","article-title":"Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance","volume":"45","author":"Al-Mansoori","year":"2022","journal-title":"Inflammation"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2015.12.021","article-title":"Effects of C-reactive protein on bone cells","volume":"145","author":"Cho","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0425","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3349\/ymj.2011.52.1.113","article-title":"The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients","volume":"52","author":"Chung","year":"2011","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0430","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/158514","article-title":"Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis","volume":"2010","author":"Meyer","year":"2010","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.bbamcr.2026.120136_bb0435","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10753-021-01559-z","article-title":"Elrayess, Role of inflammatory cytokines, growth factors and adipokines in adipogenesis and insulin resistance","volume":"45","author":"Al-Mansoori","year":"2021","journal-title":"Inflammation"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0440","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/jor.23507","article-title":"Angiopoietin-like 4: a molecular link between insulin resistance and rheumatoid arthritis","volume":"35","author":"Masuko","year":"2017","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0445","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002552","article-title":"Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study","volume":"95","author":"Ursini","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0450","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712","article-title":"Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus","volume":"27","author":"Rehman","year":"2017","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0455","first-page":"465","article-title":"Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis","volume":"37","author":"Castaneda","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196368","article-title":"Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study","volume":"13","author":"Otsuka","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014328","article-title":"Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases","volume":"5","author":"Schultz","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0470","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/annrheumdis-2018-eular.6998","article-title":"THU0219\u00a0beneficial effect of anti-il-6 blockade on insulin resistance and insulin sensitivity in patients with rheumatoid arthritis","volume":"77","author":"Remuzgo-Mart\u00ednez","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0475","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ard.2010.132845","article-title":"Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab","volume":"70","author":"Ogata","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0480","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13075-020-02229-5","article-title":"Interleukin-6 receptor blockade or TNF\u03b1 inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials","volume":"22","author":"Genovese","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0485","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/BOR.0b013e3282f798ed","article-title":"Lung disease in rheumatoid arthritis","volume":"20","author":"Nannini","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0490","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40744-017-0071-5","article-title":"Practical management of respiratory comorbidities in patients with rheumatoid arthritis","volume":"4","author":"Bluett","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0495","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ccm.2010.04.003","article-title":"Pulmonary manifestations of rheumatoid arthritis","volume":"31","author":"Antin-Ozerkis","year":"2010","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0500","doi-asserted-by":"crossref","first-page":"10953","DOI":"10.2147\/JIR.S530754","article-title":"Role of interleukin-6 in rheumatoid arthritis-associated interstitial lung disease: focus on the JAK\/STAT pathway and macrophage polarization","volume":"18","author":"Yu","year":"2025","journal-title":"JIR"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0505","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMra1705751","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"Lederer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0510","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41423-020-00608-1","article-title":"Interleukin-6 mediates neutrophil mobilization from bone marrow in pulmonary hypertension","volume":"18","author":"Florentin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0515","doi-asserted-by":"crossref","first-page":"F864","DOI":"10.1152\/ajprenal.00025.2012","article-title":"Circulating IL-6 mediates lung injury via CXCL1 production after acute kidney injury in mice","volume":"303","author":"Ahuja","year":"2012","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0520","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.ajpath.2018.03.016","article-title":"IL-6 drives neutrophil-mediated pulmonary inflammation associated with bacteremia in murine models of colitis","volume":"188","author":"Mateer","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0525","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.7150\/ijbs.75876","article-title":"The role of IL-6 in fibrotic diseases: molecular and cellular mechanisms","volume":"18","author":"Li","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0530","doi-asserted-by":"crossref","first-page":"eabo5254","DOI":"10.1126\/scitranslmed.abo5254","article-title":"Interleukin-6\u2013dependent epithelial fluidization initiates fibrotic lung remodeling","volume":"14","author":"Stancil","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0535","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12931-015-0261-z","article-title":"Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis","volume":"16","author":"Kobayashi","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0545","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.4103\/ipj.ipj_222_23","article-title":"Depression among rheumatoid arthritis patients and barriers to seeking professional help: an observational study","volume":"32","author":"Panjrattan","year":"2023","journal-title":"Ind. Psychiatry J."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0550","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-020-05326-7","article-title":"Interleukin 6, interleukin 17, disease-related and contextual factor association with depression, and its severity in patients with rheumatoid arthritis","volume":"40","author":"Albeltagy","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0555","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000097202","article-title":"Passage of cytokines across the blood-brain barrier","volume":"2","author":"Banks","year":"1995","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0560","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(94)90933-4","article-title":"Penetration of interleukin-6 across the murine blood-brain barrier","volume":"179","author":"Banks","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0565","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bbi.2018.02.003","article-title":"TNF\u03b1 disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice","volume":"69","author":"Cheng","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110903","article-title":"Potential value of Interleukin-6 as a diagnostic biomarker in human MDD and the antidepressant effect of its receptor antagonist tocilizumab in lipopolysaccharide-challenged rats","volume":"124","author":"Xu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0575","doi-asserted-by":"crossref","first-page":"8361","DOI":"10.3390\/ijms26178361","article-title":"Beyond joints: neuropsychiatric benefits of TNF-\u03b1 and IL-6 inhibitors in rheumatoid arthritis\u2014narrative review","volume":"26","author":"Siuchni\u0144ska","year":"2025","journal-title":"IJMS"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0580","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40744-020-00219-2","article-title":"Understanding the role of Interleukin-6 (IL-6) in the joint and beyond: a comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis","volume":"7","author":"Favalli","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0585","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/1756-185X.13529","article-title":"Interleukin-6 and interleukin-17 are related to depression in patients with rheumatoid arthritis","volume":"22","author":"Li","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0590","doi-asserted-by":"crossref","first-page":"383","DOI":"10.31887\/DCNS.2006.8.4\/ssmith","article-title":"The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress","volume":"8","author":"Smith","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0595","doi-asserted-by":"crossref","first-page":"II\/62","DOI":"10.1007\/s003930070020","article-title":"Correlation of IL-6 with the classical humoral disease activity parameters ESR and CRP and with serum cortisol, reflecting the activity of the HPA axis in active rheumatoid arthritis","volume":"59 Suppl 2","author":"Boss","year":"2000","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0600","doi-asserted-by":"crossref","first-page":"II75","DOI":"10.1007\/s003930070023","article-title":"Relationship between interleukin-6 (IL-6) and hypothalamic-pituitary-adrenal axis hormones in rheumatoid arthritis","volume":"59","author":"Mastorakos","year":"2000","journal-title":"Z. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0605","first-page":"1690","article-title":"Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans","volume":"77","author":"Mastorakos","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0610","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.psyneuen.2012.11.004","article-title":"Influence of hypothalamic IL-6\/gp130 receptor signaling on the HPA axis response to chronic stress","volume":"38","author":"Girotti","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0615","article-title":"Hypothalamic-pituitary-adrenal (HPA) axis: unveiling the potential mechanisms involved in stress-induced Alzheimer's disease and depression","volume":"16","author":"P","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0620","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1269378","article-title":"Circadian, hormonal, and sleep rhythms: effects on cancer progression implications for treatment","volume":"13","author":"Jagielo","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0625","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.autrev.2007.11.019","article-title":"Circadian rhythms in arthritis: hormonal effects on the immune\/inflammatory reaction","volume":"7","author":"Cutolo","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0630","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13268","article-title":"The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis","volume":"50","author":"Tiosano","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0635","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13075-020-02344-3","article-title":"High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0640","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40744-017-0081-3","article-title":"Impact of tocilizumab monotherapy on clinical and patient-reported quality-of-life outcomes in patients with rheumatoid arthritis","volume":"4","author":"Harrold","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0645","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221111613","article-title":"The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis - a pooled analysis of five randomised controlled trials","volume":"14","author":"Manning-Bennett","year":"2022","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0650","first-page":"1463","article-title":"Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study","volume":"41","author":"Behrens","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0655","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bbi.2017.06.014","article-title":"The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman\u2019s disease","volume":"66","author":"Sun","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.05.001","article-title":"The expression of interleukin-6 and its receptor in various brain regions and their roles in exploratory behavior and stress responses","volume":"284","author":"Aniszewska","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0665","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1742-2094-8-54","article-title":"Inhibition of interleukin-6 trans-signaling in the brain facilitates recovery from lipopolysaccharide-induced sickness behavior","volume":"8","author":"Burton","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0670","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1523\/JNEUROSCI.2830-13.2014","article-title":"Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain","volume":"34","author":"Campbell","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0675","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.bbi.2021.02.019","article-title":"Depression and interleukin-6 signaling: a Mendelian randomization study","volume":"95","author":"Kelly","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0680","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.neuroimage.2007.12.016","article-title":"Investigation into the neural correlates of emotional augmentation of clinical pain","volume":"40","author":"Schweinhardt","year":"2008","journal-title":"Neuroimage"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0685","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/art.10515","article-title":"Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority","volume":"47","author":"Heiberg","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0690","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/ard.2004.022699","article-title":"Seven year changes in health status and priorities for improvement of health in patients with rheumatoid arthritis","volume":"64","author":"Heiberg","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0695","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11926-012-0300-4","article-title":"Effect and treatment of chronic pain in inflammatory arthritis","volume":"15","author":"Lee","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0700","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar3353","article-title":"Pain persists in DAS28 rheumatoid arthritis remission but not in ACR\/EULAR remission: a longitudinal observational study","volume":"13","author":"Lee","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0705","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1177\/147323001003800402","article-title":"Patient perceptions concerning pain management in the treatment of rheumatoid arthritis","volume":"38","author":"Taylor","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0710","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/acr.20685","article-title":"Determinants of discordance in patients\u2019 and physicians\u2019 rating of rheumatoid arthritis disease activity","volume":"64","author":"Khan","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0715","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-017-1419-5","article-title":"Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation","volume":"19","author":"Challa","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0720","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OARRR.S291388","article-title":"Pain: a review of interleukin-6 and its roles in the pain of rheumatoid arthritis","volume":"13","author":"Sebba","year":"2021","journal-title":"Open Access Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0725","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.22282","article-title":"Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain","volume":"56","author":"Brenn","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 1","key":"10.1016\/j.bbamcr.2026.120136_bb0730","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1097\/j.pain.0000000000001333","article-title":"Pain pathogenesis in rheumatoid arthritis-what have we learned from animal models?","volume":"159","author":"Krock","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0735","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/rheumatology\/kex391","article-title":"Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis","volume":"57","author":"Choy","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0740","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/02844319109034920","article-title":"Sympathetic innervation of normal and rheumatoid synovial tissue","volume":"25","author":"Widenfalk","year":"1991","journal-title":"Scand. J. Plast. Reconstr. Surg. Hand Surg."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0745","first-page":"380","article-title":"Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality","volume":"35","author":"Nikolaisen","year":"2008","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0750","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14228","article-title":"A gp130-Src-YAP module links inflammation to epithelial regeneration","volume":"519","author":"Taniguchi","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0755","doi-asserted-by":"crossref","DOI":"10.4081\/hr.2019.7708","article-title":"Studying anemia of chronic disease and iron deficiency in patients with rheumatoid arthritis by iron status and circulating hepcidin","volume":"11","author":"Khalaf","year":"2019","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0760","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0765","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0770","doi-asserted-by":"crossref","first-page":"9263","DOI":"10.1073\/pnas.0403108101","article-title":"The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes","volume":"101","author":"Lee","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0775","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0780","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1590\/0001-3765201820170091","article-title":"Treatment with either leflunomide or adalimumab reduces anaemia in patients with rheumatoid arthritis","volume":"90","author":"Pereira","year":"2018","journal-title":"An. Acad. Bras. Cienc."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0785","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/0394632017714695","article-title":"Anti-TNF-\u03b1 effects on anemia in rheumatoid and psoriatic arthritis","volume":"30","author":"Corrado","year":"2017","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0790","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-\u03b1 inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0795","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar4397","article-title":"Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis","volume":"15","author":"Isaacs","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0800","doi-asserted-by":"crossref","first-page":"135","DOI":"10.14740\/jmc3902","article-title":"Tocilizumab-associated small bowel perforation in a young patient with rheumatoid arthritis: a lesson to remember during COVID-19 pandemic","volume":"13","author":"Saad","year":"2022","journal-title":"J. Med. Cases"},{"key":"10.1016\/j.bbamcr.2026.120136_bb0805","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0810","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40744-016-0037-z","article-title":"Incidence of gastrointestinal perforations in patients with rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing, and real-world data sources","volume":"3","author":"Monemi","year":"2016","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0815","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/febs.17355","article-title":"More and more pleiotropy within the IL-6 family of cytokines","volume":"292","author":"Rose-John","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0820","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2353\/ajpath.2007.061078","article-title":"Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo","volume":"171","author":"Coles","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbamcr.2026.120136_bb0825","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926000327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167488926000327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T16:03:10Z","timestamp":1776700990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167488926000327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":160,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0167488926000327"],"URL":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120136","relation":{},"ISSN":["0167-4889"],"issn-type":[{"value":"0167-4889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of IL-6 in rheumatoid arthritis comorbidity and implications for therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbamcr.2026.120136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120136"}}